Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft Outcome

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

Bone Marrow Transplantation volume 27, pages 1037–1043 (2001)Cite this article

Abstract

Clinical outcomes were assessed in 68 consecutive patients with multiple myeloma of high or intermediate tumor mass that had responded to VAD or dexamethasone-based therapy and were consolidated with early intensive therapy and autologous stem cell transplantation. Results were compared with those of 50 comparable patients who refused or were unable to receive intensive treatment for socioeconomic reasons. Following high-dose therapy, the rate of CR increased from 6 to 37%, with median survival prolonged by 10 months. Survival of 21 patients with disease converted from PR to CR (median 8.3 years) was significantly longer than that of similarly-treated patients who remained in PR (median 5.0 years). CR of myeloma represents the major surrogate marker of long survival and the primary goal of myeloablative treatment for patients in PR. Twelve of 18 patients with rapid reduction of myeloma protein (T½ < 0.5 months), and myeloma protein reduction to <1.0 g/dl after primary therapy achieved CR (67%), identifying pretransplant features favorable to intensive therapy. Among 35 patients with slower reduction or higher residual myeloma protein, CR occurred in eight patients (23%) (P < 0.01), for whom other treatments should be considered. The kinetics of response to initial therapy should be considered in selecting patients more likely to achieve CR and consequent long survival after intensive treatment. Bone Marrow Transplantation (2001) 27, 1037–1043.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Barlogie B, Alexanian R, Dicke K et al. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma Blood 1987 70: 868–872

    Google Scholar 

  2. Cunningham D, Pazares L, Gore M et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated multiple myeloma J Clin Oncol 1994 12: 759–763

    Article  CAS  PubMed  Google Scholar 

  3. Alexanian R, Dimopoulos M, Hester J et al. Early myeloablative therapy for multiple myeloma Blood 1994 84: 4278–4282

    CAS  PubMed  Google Scholar 

  4. Harousseau J, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma Blood 1995 85: 3077–3085

    CAS  PubMed  Google Scholar 

  5. Attal M, Harousseau J, Stoppa J et al. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–97

    Article  CAS  PubMed  Google Scholar 

  6. Bensinger W, Rowley S, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma J Clin Oncol 1996 14: 1447–1456

    Article  CAS  PubMed  Google Scholar 

  7. Barlogie B, Jagannath S, Vesole D et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 1997 89: 789–793

    CAS  PubMed  Google Scholar 

  8. Fermand J-P, Chevret S, Ravaud P et al. High dose therapy and autologous blood stem cell transplantation in multiple myeloma Blood 1998 92: 3191–3196

    Google Scholar 

  9. Blade J, San Miguel J, Fontanillas M et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation who were conventionally treated J Clin Oncol 1996 14: 2167–2173

    Article  CAS  PubMed  Google Scholar 

  10. Fermand J-P, Ravaud P, Katsahian S et al. High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma Blood 1999 94: 396a (Abstr. 1754)

    Google Scholar 

  11. Tricot G, Barlogie B, Jagannath S et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 and not with other karyotype abnormalities Blood 1995 86: 4250–4256

    CAS  PubMed  Google Scholar 

  12. Lahuerta J, Martinez-Lopez J, de la Serna J et al. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients Br J Haematol 2000 109: 438–446

    Article  CAS  PubMed  Google Scholar 

  13. Alexanian R, Barlogie B, Tucker S . VAD-based regimens as primary treatment for multiple myeloma Am J Hematol 1990 33: 86–89

    Article  CAS  PubMed  Google Scholar 

  14. Alexanian R, Dimopoulos M, Delasalle K, Barlogie B . Primary dexamethasone treatment of multiple myeloma Blood 1992 80: 887–890

    CAS  PubMed  Google Scholar 

  15. Dimopoulos M, Weber D, Kantarjian H et al. HyperCVAD for VAD-resistant multiple myeloma Am J Hematol 1996 52: 77–81

    Article  CAS  PubMed  Google Scholar 

  16. Dimopoulos M, Alexanian R, Przepiorka D et al. A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma Blood 1993 82: 2324–2328

    CAS  PubMed  Google Scholar 

  17. Giralt S, Weber D, Colome M et al. Phase I trial of cyclosporine-induced graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem cell rescue J Clin Oncol 1997 15: 667–673

    Article  CAS  PubMed  Google Scholar 

  18. McLaughlin P, Alexanian R . Myeloma protein kinetics following chemotherapy Blood 1982 60: 851–855

    CAS  PubMed  Google Scholar 

  19. Siegel D, Desikan K, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma Blood 1999 93: 51–54

    CAS  PubMed  Google Scholar 

  20. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma Blood 2000 95: 7–11

    CAS  PubMed  Google Scholar 

  21. Harousseau J, Facon T, Moreau P et al. Comparison of high-dose melphalan 140 mg/m2 plus total body irradiation and high-dose melphalan 200 mg/m2 as conditioning regimen for peripheral blood progenitor cell autotransplantation in patients with newly diagnosed multiple myeloma Blood 1999 94: 713a (Abstr. 3150)

    Google Scholar 

  22. Champlin R, Giralt S, Eary J et al. 166Holmium-DOTMP in combination with melphalan with or without total body irradiation as a preparative regimen for autologous stem cell transplant for patients with multiple myeloma Blood 1999 94: 709a (Abstr. 3133)

    Google Scholar 

  23. Giralt S, Weber D, Aleman A et al. Non myeloablative conditioning with fludarabine/melphalan for patients with multiple myeloma Blood 1999 94: 347a (Abstr. 1549)

    Google Scholar 

  24. Stewart A, Schiller G, Vescio R et al. CD34 selection does not prolong disease free or overall survival in myeloma patients undergoing autologous stem cell transplant Blood 1999 94: 714a (Abstr. 3151)

    Google Scholar 

  25. Osterborg A, Yi Q, Henriksson L et al. Idiotype immunization combined with granulocyte–macrophage colony-stimulating factor in myeloma patients induced type 1, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses Blood 1998 91: 2459–2464

    CAS  PubMed  Google Scholar 

  26. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma New Engl J Med 1999 341: 1565–1571

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Rose Guevara for the careful preparation of the manuscript. This work was supported by the Lucille Murchison and Kay Laro research funds.

Author information

Authors and Affiliations

  1. University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    R Alexanian, D Weber, S Giralt, M Dimopoulos, K Delasalle, T Smith & R Champlin

Authors
  1. R Alexanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Dimopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Delasalle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alexanian, R., Weber, D., Giralt, S. et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 27, 1037–1043 (2001). https://doi.org/10.1038/sj.bmt.1703035

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703035

Keywords

This article is cited by

Search

Advanced search

Quick links